Both GW4869 and Imip treatments resulted in a significant suppression of IL-1b and IL-6 gene expression, reinforcing the anti-inflammatory effects of inhibiting sphingomyelinase pathways in the context of hepatic steatosis. This evidence concerns the gene IL6 and fatty liver disease.